U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07439536) titled 'Dose Optimization of Sitagliptin and Duloxetine in Diabetic Cirrhosis' on Feb. 17.
Brief Summary: This study was a prospective, interventional, two-part pilot clinical study conducted over 3 months on cirrhotic patients with diabetes mellitus and diabetic neuropathy, evaluating the real-world applicability of selected PBPK-guided dosing regimens. Patients were stratified according to Child-Pugh class (CP-A , CP-B, and CP-C) in case of sitagliptin and CP-A in duloxetine at doses corresponding to the closest commercially available strengths to Simcyp(R)-optimized doses.
Clinical evaluation included glycemic parameters(HbA1C,fasting b...